Company Overview - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily oral PDE4 inhibitor prodrugs aimed at targeted delivery to the terminal ileum and colon [2][6] - The company's lead program, PALI-2108, is designed to improve pharmacology, tolerability, and convenience for patients with inflammatory and fibrotic diseases [6][7] Product Details - PALI-2108 is a once-daily oral prodrug that is pharmacologically inactive until it reaches the lower intestine, where it is activated by bacterial enzymes at sites of inflammation and fibrosis [5][7] - In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in the ulcerative colitis (UC) cohort, with no serious adverse events reported [7] - The company is advancing towards a Phase 2 clinical study in UC, which will evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks [8] Upcoming Events - JD Finley, CEO, and Dr. Mitchell Jones, President and CMO, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026 [2][3] - A live webcast of the presentation will be available on the company's website, with a replay accessible for a limited time [4]

Core Viewpoint - Palisade Bio, Inc. is advancing its clinical-stage biopharmaceutical product, PALI-2108, a once-daily oral PDE4 inhibitor prodrug aimed at treating inflammatory and fibrotic diseases, with a focus on targeted delivery to the terminal ileum and colon [2][6]. Group 1: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation oral PDE4 inhibitor prodrugs to enhance pharmacology, tolerability, and convenience for patients [6]. - The company is committed to transforming established PDE4 biology into safer oral therapies for chronic inflammatory and fibrotic diseases through its differentiated prodrug platform [6]. Group 2: Product Details - PALI-2108 is designed for targeted delivery of PDE4 inhibition to the terminal ileum and colon, activated by local bacterial bioactivation, which minimizes systemic absorption and improves tolerability [5]. - In a Phase 1b trial, PALI-2108 demonstrated a 100% clinical response in the ulcerative colitis (UC) cohort, with no serious adverse events and favorable pharmacokinetics [7]. Group 3: Clinical Development - The company is progressing towards a Phase 2 clinical study in UC, which will evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, including an extension phase for maintenance of remission [8]. - Early studies are being completed in fibrotic diseases to further assess PALI-2108's safety, pharmacology, and potential therapeutic benefits across inflammatory bowel disease indications [8].

Core Insights - Palisade Bio has appointed Dr. Laurent Peyrin-Biroulet and Dr. David T. Rubin to its Clinical Advisory Board, enhancing its clinical strategy as it advances PALI-2108 towards Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease [1][2] Company Overview - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation oral PDE4 inhibitor prodrugs aimed at targeted delivery to the terminal ileum and colon [1][10] - The lead program, PALI-2108, is designed for once-daily oral administration and is pharmacologically inactive until it reaches the lower intestine, where it is activated by bacterial enzymes [9][11] Clinical Development - PALI-2108 has shown a 100% clinical response in a Phase 1b trial for ulcerative colitis, with no serious adverse events reported [11] - The company plans to submit an IND for a Phase 2 clinical study in ulcerative colitis in the first half of 2026, focusing on clinical remission and pharmacodynamic biomarkers over a 12-week period [1][12] Advisory Board Expertise - Dr. Peyrin-Biroulet is a leading authority in inflammatory bowel disease, with over 1200 peer-reviewed publications and significant roles in major IBD organizations [4][5] - Dr. Rubin is recognized for his expertise in clinical trial design and has been instrumental in the development of numerous approved IBD therapies [7][8]

Core Insights - Palisade Bio, Inc. is advancing its lead program, PALI-2108, a gut-targeted PDE4 inhibitor for ulcerative colitis, with two abstracts selected for presentation at major IBD conferences in early 2026 [1][3][4] Group 1: Product Development - PALI-2108 is designed for local delivery of PDE4 inhibition specifically to the terminal ileum and colon, minimizing systemic exposure and enhancing therapeutic index [4][7] - The prodrug is activated in the lower intestine, allowing for sustained local exposure and once-daily dosing, which aims to improve tolerability compared to systemic PDE4 inhibitors [4][7] - In a Phase 1b trial, PALI-2108 achieved a 100% clinical response in the ulcerative colitis cohort, with no serious adverse events reported [7] Group 2: Clinical Engagement - The Crohn's & Colitis Congress 2026 will feature a poster presentation on PALI-2108's ability to restore immune-epithelial balance in ulcerative colitis [2] - The 21st Congress of ECCO will also showcase findings from a Phase 1a study demonstrating clinical, histologic, and biomarker improvements with PALI-2108 [3] - The company aims to engage with the global IBD community to discuss these findings and the potential of PALI-2108 [3] Group 3: Future Plans - Palisade Bio is preparing to initiate a Phase 2 clinical study in ulcerative colitis, focusing on clinical remission and pharmacodynamic biomarkers over a 12-week period [8] - The company is also planning studies in fibrostenotic Crohn's Disease to further evaluate PALI-2108's safety and therapeutic benefits [8]

Core Viewpoint - Palisade Bio, Inc. is advancing PALI-2108, a novel PDE4 inhibitor targeting ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD), addressing significant unmet medical needs in these conditions [1][3] Intellectual Property - The Japan Patent Office has granted a key patent for PALI-2108, providing composition-of-matter protection until 2041, with potential extensions based on regulatory review timelines [2] - This patent strengthens Palisade Bio's global intellectual property portfolio, supporting the development of PALI-2108 and its broader platform of locally activated PDE4 inhibitor prodrugs [2][3] Clinical Development - PALI-2108 has completed Phase 1a studies and is currently in a Phase 1b cohort study for both UC and FSCD, with Phase 2 IND submissions planned for the first half of 2026 [1][3][6] - In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, demonstrating favorable tolerability and pharmacokinetics [6] Mechanism and Design - PALI-2108 is designed for local delivery of PDE4 inhibition specifically to the terminal ileum and colon, minimizing systemic exposure and enhancing therapeutic index [4] - The prodrug is activated by gut microbiota, ensuring targeted release at the site of inflammation and fibrosis, which aims to improve anti-inflammatory and anti-fibrotic effects while reducing common side effects associated with systemic PDE4 inhibitors [4][6] Future Plans - The company is preparing to initiate a Phase 2 clinical study in UC to evaluate clinical remission and pharmacodynamic biomarkers over 12 weeks, with an extension phase for maintenance of remission [7] - Additionally, studies in FSCD are planned to further characterize the safety and therapeutic benefits of PALI-2108 across inflammatory bowel disease indications [7]

Core Viewpoint - Palisade Bio, Inc. has appointed Dr. James Izanec as Vice President of Clinical Development, bringing extensive experience in leading global Phase 2/3 programs in immunology, neurology, and gastroenterology [1][3][4] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases [8][10] - The lead program, PALI-2108, targets moderate-to-severe Ulcerative Colitis (UC) and Fibrostenotic Crohn's Disease (FSCD), with a recent Phase 1b trial showing a 100% clinical response in the UC cohort [10][11] Leadership and Experience - Dr. Izanec has over two decades of experience in clinical and drug development, having previously held senior roles at Bristol Myers Squibb and Janssen [3][4][5] - His background includes overseeing a 1,200-patient Phase 3 Crohn's program and leading pediatric development programs in related diseases [4][5] Clinical Development Strategy - The company is advancing PALI-2108 towards a Phase 2 clinical study in UC, focusing on clinical remission, response, and pharmacodynamic biomarkers over 12 weeks [11] - Plans are also in place to initiate studies in FSCD to further evaluate PALI-2108's safety and therapeutic benefits [11]

Core Insights - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases [3][4] - The company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, featuring CEO JD Finley and CMO Dr. Mitchell Jones [1][2] Company Overview - Palisade Bio is dedicated to improving pharmacology, tolerability, and convenience for patients suffering from chronic inflammatory and fibrotic diseases through its differentiated prodrug platform and precision pharmacology strategy [3] - The lead program, PALI-2108, is being developed for moderate-to-severe Ulcerative Colitis (UC) and Fibrostenotic Crohn's Disease (FSCD), addressing the need for non-immunosuppressive therapy options [4] Clinical Development - In a Phase 1b trial, PALI-2108 demonstrated a 100% clinical response in the UC cohort, with no serious adverse events and favorable tolerability [4] - The company is advancing towards a Phase 2 clinical study in UC to evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks, with plans for an extension phase [5] - Additionally, studies in FSCD are being prepared to further assess PALI-2108's safety, pharmacology, and therapeutic benefits across inflammatory bowel disease indications [5]